

# STATE OF NEW YORK

5282

2025-2026 Regular Sessions

## IN ASSEMBLY

February 12, 2025

Introduced by M. of A. SOLAGES, TAYLOR, SEAWRIGHT, RAMOS, SIMON, ROSEN-  
THAL, GLICK, BENDETT -- read once and referred to the Committee on  
Insurance

AN ACT to amend the insurance law and the public health law, in relation  
to access to appropriate drugs at reasonable prices, formulary  
exceptions, standing prior authorizations and external appeals; to  
amend the insurance law, in relation to access to retail pharmacies,  
prescription synchronization, limits on patient drug costs, explana-  
tions of benefits and rebates; to amend the social services law, in  
relation to prescription drug synchronization; and to amend the educa-  
tion law, in relation to limits on copayments and drug substitutions

The People of the State of New York, represented in Senate and Assem-  
bly, do enact as follows:

1 Section 1. The insurance law is amended by adding a new section 4807  
2 to read as follows:

3 § 4807. Access to appropriate drugs at reasonable prices; formulary  
4 exceptions; standing prior authorization requirement. (a) An insurer  
5 offering a prescription drug benefit with a formulary of approved or  
6 preferred drugs shall establish a procedure by which it determines  
7 whether a formulary drug provides appropriate therapeutic benefits to  
8 meet the particular health care needs of an insured. If the insurer  
9 determines that no formulary drug provides appropriate therapeutic bene-  
10 fits to meet the particular health care needs of an insured, the insurer  
11 shall cover the cost of an off-formulary drug for that insured, at no  
12 additional cost to the insured beyond what the insured would otherwise  
13 pay for a preferred brand name drug on the formulary. The determinations  
14 whether a drug provides appropriate therapeutic benefits and whether a  
15 non-formulary drug is necessary to meet the particular health care needs  
16 of the insured are utilization review decisions and are reviewable in  
17 accordance with article forty-nine of this chapter, including external  
18 appeal.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets  
[-] is old law to be omitted.

LBD09173-01-5

1 (b) (1) For purposes of this section, "prior authorization require-  
2 ment" means any practice implemented by an insurer in which coverage of  
3 a prescription drug or device is dependent upon a covered person or a  
4 health care practitioner obtaining approval from the insurer prior to  
5 the service, device, or drug being performed, received, or prescribed,  
6 as applicable. "Prior authorization" includes prospective or utilization  
7 review procedures conducted prior to providing a drug or device.

8 (2) An insurer which requires prior authorizations for particular  
9 prescription drugs shall have a procedure by which an insured who is  
10 being prescribed such drug for a chronic condition may obtain a standing  
11 prior authorization for a drug for the lesser of the following from the  
12 date of the approval: (i) twelve months; or (ii) the last day of the  
13 covered person's eligibility under the policy or plan.

14 (3) As a condition of such standing prior authorization, if according  
15 to the available medical and scientific evidence the patient's chronic  
16 condition is likely to change during the standing referral period, the  
17 insurer or health plan may require the prescribing health care practi-  
18 tioner to certify to the insurer, not more frequently than on a quarter-  
19 ly basis, that the patient's chronic condition has not changed mate-  
20 rially with respect to the need for the prescription.

21 (4) A twelve-month standing prior authorization provided under para-  
22 graph two of this subsection does not apply to and is not required for  
23 any of the following:

24 (i) medications that have a typical course of administration of less  
25 than one year or for which available medical or scientific evidence does  
26 not support a twelve-month period of use, in which case the standing  
27 prior authorization period shall be the typical course of administration  
28 or the period of use supported by the available medical or scientific  
29 evidence;

30 (ii) medications that require an initial trial period to determine  
31 effectiveness and tolerability, except that after such trial period a  
32 one-year, or greater, prior authorization period will be given; and

33 (iii) medications that are schedule II controlled substance or a sche-  
34 dule III controlled substance containing hydrocodone.

35 (5) For drugs used to treat acute conditions, insurers shall grant  
36 standing prior authorizations for the period that the medical and scien-  
37 tific evidence shows to be the anticipated period for the course of  
38 treatment to have its intended effect.

39 (6) The standing prior authorizations provided for in this section are  
40 no longer valid and automatically terminate if there are changes to  
41 federal or state laws or federal regulatory guidance or compliance  
42 information finding that the drug in question is no longer approved or  
43 safe for the prescribed purpose.

44 (7) If an AB-rated generic drug that is therapeutically equivalent to  
45 the drug subject to a standing prior authorization becomes available,  
46 the insurer may substitute such newly released drug for the drug subject  
47 to the standing prior authorization, provided advance notice is given to  
48 the insured.

49 (8) The determination whether the drug is being prescribed to treat a  
50 chronic condition and the period over which the course of treatment for  
51 an acute condition is anticipated to have its intended effect are utili-  
52 zation review decisions and are reviewable in accordance with article  
53 forty-nine of this chapter, including external appeal.

54 (c) (1) If a formulary drug being prescribed for an insured is removed  
55 by the insurer from its formulary for reasons other than a determination  
56 that the approval for the use of that drug has been withdrawn by the

1 U.S. Food and Drug Administration, the insurer shall continue to cover  
2 that drug for that insured for a transitional period to the end of the  
3 plan year at the same copayment as charged when the drug was on formu-  
4 lary. Thereafter, the insured may seek continued coverage of the drug,  
5 if appropriate, pursuant to the provisions of subsection (a) of this  
6 section.

7 (2) If a formulary drug being prescribed for an insured is moved by  
8 the insurer to a higher cost sharing tier in its formulary for reasons  
9 other than release of an AB-rated generic drug, the insurer shall  
10 continue to cover that drug for that insured for a transitional period  
11 to the end of the plan year at the same copayment as charged when the  
12 drug was on formulary. Thereafter, the insured may seek continued cover-  
13 age of the drug, if appropriate, pursuant to the provisions of  
14 subsection (a) of this section.

15 (3) If an insurer that provides prescription drug coverage enrolls a  
16 new insured who is currently being prescribed a drug for a chronic  
17 health condition, or as part of an ongoing course of treatment for an  
18 acute condition, and that drug is not on the insurer's formulary, the  
19 insurer shall cover that drug for that insured at no additional cost to  
20 the insured beyond what the insured would otherwise pay for a preferred  
21 brand name drug on the formulary, for a transitional period of ninety  
22 (90) days from the effective date of enrollment. The insured must adhere  
23 to the insurer's quality assurance requirements and provide to the  
24 insurer necessary medical information related to the prescription and  
25 otherwise adhere to the insurer's policies and procedures including, but  
26 not limited to procedures regarding obtaining pre-authorization and a  
27 treatment plan approved by the insurer. In no event shall this  
28 subsection be construed to require an insurer to provide coverage for  
29 benefits not otherwise covered. The transitional period does not  
30 preclude the insured from seeking continued coverage of the drug, if  
31 appropriate, pursuant to the provisions of subsection (a) of this  
32 section.

33 § 2. The public health law is amended by adding a new section 4406-j  
34 to read as follows:

35 § 4406-j. Access to appropriate drugs at reasonable prices; formulary  
36 exceptions; standing prior authorization requirement. 1. A health main-  
37 tenance organization offering a prescription drug benefit with a formu-  
38 lary of approved or preferred drugs shall have a procedure by which it  
39 determines whether a formulary drug provides appropriate therapeutic  
40 benefits to meet the particular health care needs of an enrollee. If the  
41 health maintenance organization determines that no formulary drug  
42 provides appropriate therapeutic benefits to meet the particular health  
43 care needs of an enrollee, the health maintenance organization shall  
44 cover the cost of an off-formulary drug for that enrollee, at no addi-  
45 tional cost to the enrollee beyond what the enrollee would otherwise pay  
46 for a preferred brand name drug on the formulary. The determinations  
47 whether a drug provides appropriate therapeutic benefits and whether a  
48 non-formulary drug is necessary to meet the particular health care needs  
49 of the insured are utilization review decisions and are reviewable in  
50 accordance with article forty-nine of this chapter, including external  
51 appeal.

52 2. (a) For purposes of this section, "prior authorization requirement"  
53 means any practice implemented by a health maintenance organization in  
54 which coverage of a prescription drug or device is dependent upon a  
55 covered person or a health care practitioner obtaining approval from the  
56 health maintenance organization prior to the service, device, or drug

1 being performed, received, or prescribed, as applicable. "Prior authori-  
2 zation" includes prospective or utilization review procedures conducted  
3 prior to providing a drug or device.

4 (b) A health maintenance organization which requires prior authori-  
5 zations for particular prescription drugs shall have a procedure by  
6 which an enrollee who is being prescribed such drug for a chronic condi-  
7 tion may obtain a standing prior authorization for a drug for the lesser  
8 of the following from the date of the approval: (i) twelve months; (ii)  
9 the last day of the enrollee's eligibility under the policy or plan.

10 (c) As a condition of such standing prior authorization, if according  
11 to the available medical and scientific evidence the enrollee's chronic  
12 condition is likely to change during the standing referral period, the  
13 insurer or health plan may require the prescribing health care practi-  
14 tioner to certify to the health maintenance organization, not more  
15 frequently than on a quarterly basis, that the enrollee's chronic condi-  
16 tion has not changed materially with respect to the need for the  
17 prescription.

18 (d) A twelve-month standing prior authorization provided under subpar-  
19 agraph (i) of paragraph (b) of this subdivision does not apply to and is  
20 not required for any of the following:

21 (i) medications that have a typical course of administration of less  
22 than one year or for which available medical or scientific evidence does  
23 not support a twelve-month period of use, in which case the standing  
24 prior authorization period shall be the typical course of administration  
25 or the period of use supported by the available medical or scientific  
26 evidence;

27 (ii) medications that require an initial trial period to determine  
28 effectiveness and tolerability, except that after such trial period a  
29 one-year, or greater, prior authorization period will be given; and

30 (iii) medications that are schedule II controlled substance or a sche-  
31 dule III controlled substance containing hydrocodone.

32 (e) For drugs used to treat acute conditions, insurers shall grant  
33 standing prior authorizations for the period that the medical and scien-  
34 tific evidence shows to be the anticipated period for the course of  
35 treatment to have its intended effect.

36 (f) The standing prior authorizations provided for in this section are  
37 no longer valid and automatically terminate if there are changes to  
38 federal or state laws or federal regulatory guidance or compliance  
39 information finding that the drug in question is no longer approved or  
40 safe for the prescribed purpose.

41 (g) If an AB-rated generic drug that is therapeutically equivalent to  
42 the drug subject to a standing prior authorization becomes available,  
43 the health maintenance organization may substitute such newly released  
44 drug for the drug subject to the standing prior authorization, provided  
45 advance notice is given to the enrollee.

46 (h) The determination whether the drug is being prescribed to treat a  
47 chronic condition and the period over which the course of treatment for  
48 an acute condition is anticipated to have its intended effect are utili-  
49 zation review decisions and are reviewable in accordance with article  
50 forty-nine of this chapter, including external appeal.

51 3. (a) If a formulary drug being prescribed for an enrollee is removed  
52 by the health maintenance organization from its formulary for reasons  
53 other than a determination that the approval for the use of that drug  
54 has been withdrawn by the U.S. Food and Drug Administration, the health  
55 maintenance organization shall continue to cover that drug for that  
56 enrollee for a transitional period to the end of the plan year at the

1 same copayment as charged when the drug was on formulary. Thereafter,  
2 the enrollee may seek continued coverage of the drug, if appropriate,  
3 pursuant to the provisions of subdivision one of this section.

4 (b) If a formulary drug being prescribed for an insured is moved by  
5 the health maintenance organization to a higher cost sharing tier in its  
6 formulary for reasons other than release of an AB-rated generic drug,  
7 the health maintenance organization shall continue to cover that drug  
8 for that enrollee for a transitional period to the end of the plan year  
9 at the same copayment as charged when the drug was on formulary. There-  
10 after, the enrollee may seek continued coverage of the drug, if appro-  
11 priate, pursuant to the provisions of subdivision one of this section.

12 (c) If a health maintenance organization that provides prescription  
13 drug coverage enrolls a new enrollee who is currently being prescribed a  
14 drug for a chronic health condition, or as part of an ongoing course of  
15 treatment for an acute condition, and that drug is not on the health  
16 maintenance organization's formulary, the health maintenance organiza-  
17 tion shall cover that drug for that enrollee at no additional cost to  
18 the enrollee beyond what the enrollee would otherwise pay for a  
19 preferred brand name drug on the formulary, for a transitional period of  
20 ninety (90) days from the effective date of enrollment. The enrollee  
21 must adhere to the health maintenance organization's quality assurance  
22 requirements and provide to the health maintenance organization neces-  
23 sary medical information related to the prescription and otherwise  
24 adhere to the health maintenance organization's policies and procedures  
25 including, but not limited to procedures regarding obtaining pre-author-  
26 ization and a treatment plan approved by the health maintenance organ-  
27 ization. In no event shall this subdivision be construed to require a  
28 health maintenance organization to provide coverage for benefits not  
29 otherwise covered. The transitional period does not preclude the enrol-  
30 lee from seeking continued coverage of the drug, if appropriate, pursu-  
31 ant to the provisions of subdivision one of this section.

32 § 3. Section 4903 of the insurance law is amended by adding a new  
33 subsection (j) to read as follows:

34 (j) (1) Each health plan shall make available to all participating  
35 health care providers on its web site or provider portal a listing of  
36 its prior authorization requirements, including specific information or  
37 documentation that a provider must submit in order for the prior author-  
38 ization request to be considered complete.

39 (2) Each health plan shall make available on its web site information  
40 about the policies, contracts, or agreements offered by it that clearly  
41 identifies specific services, drugs, or devices to which a prior author-  
42 ization requirement exists.

43 (3) Each health plan shall give thirty (30) days advance written  
44 notice to participating providers of any changes in prior authorization  
45 requirements. Each health plan shall also give thirty (30) days advance  
46 written notice to plan participants of any changes in prior authori-  
47 zation requirements with respect to any services, drugs or devices which  
48 such participant is currently being prescribed or has been prescribed in  
49 the preceding year.

50 § 4. Section 4903 of the public health law is amended by adding a new  
51 subdivision 10 to read as follows:

52 10. (a) Each health plan shall make available to all participating  
53 health care providers on its web site or provider portal a listing of  
54 its prior authorization requirements, including specific information or  
55 documentation that a provider must submit in order for the prior author-  
56 ization request to be considered complete.

1 (b) Each health plan shall make available on its web site information  
2 about the policies, contracts, or agreements offered by it that clearly  
3 identifies specific services, drugs, or devices to which a prior author-  
4 ization requirement exists.

5 (c) Each health plan shall give thirty (30) days advance written  
6 notice to participating providers of any changes in prior authorization  
7 requirements. Each health plan shall also give thirty (30) days advance  
8 written notice to plan participants of any changes in prior authori-  
9 zation requirements with respect to any services, drugs or devices which  
10 such participant is currently being prescribed or has been prescribed in  
11 the preceding year.

12 § 5. Subsection (b) of section 4910 of the insurance law is amended by  
13 adding a new paragraph 5 to read as follows:

14 (5) (A) The insured has had a drug prescription denied on the ground  
15 that it is not on the health care plan's formulary, and that the health  
16 care plan has a covered drug on the formulary which is effective to meet  
17 the particular health care needs of an insured; and

18 (B) The insured's attending physician, who shall be a licensed physi-  
19 cian or other health care provider qualified to prescribe drugs to treat  
20 the insured for the health service sought, certifies that available  
21 formulary drugs are not sufficiently effective to meet the insured's  
22 health needs, or are otherwise contraindicated for the insured, and  
23 recommends an off-formulary drug that will be effective to treat the  
24 insured.

25 § 6. Subdivision 2 of section 4910 of the public health law is amended  
26 by adding a new paragraph (e) to read as follows:

27 (e) (i) The enrollee has had a drug prescription denied on the ground  
28 that it is not on the health maintenance organization's formulary, and  
29 that the health maintenance organization has a covered drug on the  
30 formulary which is effective to meet the particular health care needs of  
31 an enrollee; and

32 (ii) The enrollee's attending physician, who shall be a licensed  
33 physician or other health care provider qualified to prescribe drugs to  
34 treat the insured for the health service sought, certifies that avail-  
35 able formulary drugs are not sufficiently effective to meet the  
36 enrollee's health needs, or are otherwise contraindicated for the enrol-  
37 lee, and recommends an off-formulary drug that will be effective to  
38 treat the enrollee.

39 § 7. Paragraph 4 of subsection (b) of section 4914 of the insurance  
40 law is amended by adding a new subparagraph (E) to read as follows:

41 (E) For external appeals requested pursuant to paragraph five of  
42 subsection (b) of section four thousand nine hundred ten of this title  
43 relating to an off-formulary drug denial, the external appeal agent  
44 shall review the utilization review agent's final adverse determination  
45 and, in accordance with the provisions of this title, shall make a  
46 determination as to whether the non-formulary drug shall be covered by  
47 the health plan; provided that such determination shall:

48 (i) be conducted only by one or a greater odd number of clinical peer  
49 reviewers;

50 (ii) be accompanied by a written statement:

51 (I) that the off-formulary drug prescription shall be covered by the  
52 health care plan either when the reviewer or a majority of the panel of  
53 reviewers determines, upon review of the available medical and scientif-  
54 ic evidence, the formulary drug deemed sufficient by the health plan  
55 will not be as effective in addressing the insured's health problem for  
56 which a drug has been prescribed as the off-formulary drug prescribed by

1 the treating physician or otherwise be appropriate to meet the partic-  
2 ular health care needs of the insured, which is more likely to provide a  
3 beneficial clinical outcome; or

4 (II) upholding the health plan's denial of coverage.

5 § 8. Paragraph (d) of subdivision 2 of section 4914 of the public  
6 health law is amended by adding a new subparagraph (E) to read as  
7 follows:

8 (E) For external appeals requested pursuant to paragraph (e) of subdivi-  
9 vision two of section forty-nine hundred ten of this title relating to  
10 an off-formulary drug denial, the external appeal agent shall review the  
11 utilization review agent's final adverse determination and, in accord-  
12 ance with the provisions of this title, shall make a determination as to  
13 whether the non-formulary drug shall be covered by the health mainte-  
14 nance organization; provided that such determination shall:

15 (i) be conducted only by one or a greater odd number of clinical peer  
16 reviewers;

17 (ii) be accompanied by a written statement:

18 (1) that the off-formulary drug prescription shall be covered by the  
19 health maintenance organization either when the reviewer or a majority  
20 of the panel of reviewers determines, upon review of the available  
21 medical and scientific evidence, the formulary drug deemed sufficient by  
22 the health maintenance organization will not be as effective in address-  
23 ing the enrollee's health problem for which a drug has been prescribed  
24 as the off-formulary drug prescribed by the treating physician or other-  
25 wise be appropriate to meet the particular health care needs of the  
26 enrollee, which is more likely to provide a beneficial clinical outcome;  
27 or

28 (2) upholding the health maintenance organization's denial of cover-  
29 age.

30 § 9. The opening paragraph of paragraph 28 of subsection (i) of  
31 section 3216 of the insurance law is designated subparagraph (A) and a  
32 new subparagraph (B) is added to read as follows:

33 (B) Notwithstanding any other provision of this paragraph, if a pres-  
34 criber, after consulting with the insurer regarding the appropriateness  
35 of mail order delivery given: (i) the residence or delivery location of  
36 the insured; (ii) the medical condition of the insured; (iii) the stor-  
37 age requirements of the drug; (iv) the availability of the insured to  
38 receive the prescription; or (v) the insured's ability to comprehend  
39 pharmaceutical guidance and support over the telephone, determines that  
40 a drug as prescribed on an individual basis is most appropriately filled  
41 at a retail location, provided that an in-network retail pharmacy of the  
42 patient's choosing agrees to the same reimbursement amount and is able  
43 to fill the prescription, the prescriber's determination shall be final.

44 § 10. The opening paragraph of paragraph 18 of subsection (1) of  
45 section 3221 of the insurance law is designated subparagraph (A) and a  
46 new subparagraph (B) is added to read as follows:

47 (B) Notwithstanding any other provision of this paragraph, if a pres-  
48 criber, after consulting with the insurer regarding the appropriateness  
49 of mail order delivery given: (i) the residence or delivery location of  
50 the insured; (ii) the medical condition of the insured; (iii) the stor-  
51 age requirements of the drug; (iv) the availability of the insured to  
52 receive the prescription; or (v) the insured's ability to comprehend  
53 pharmaceutical guidance and support over the telephone, determines that  
54 a drug as prescribed on an individual basis is most appropriately filled  
55 at a retail location, provided that an in-network retail pharmacy of the

1 patient's choosing agrees to the same reimbursement amount and is able  
2 to fill the prescription, the prescriber's determination shall be final.

3 § 11. Subsection (kk) of section 4303 of the insurance law is amended  
4 by adding a new paragraph 3 to read as follows:

5 (3) Notwithstanding any other provision of this subsection, if a pres-  
6 criber, after consulting with the insurer regarding the appropriateness  
7 of mail order delivery given: (A) the residence or delivery location of  
8 the covered person; (B) the medical condition of the covered person; (C)  
9 the storage requirements of the drug; (D) the availability of the  
10 covered person to receive the prescription; or (E) the covered person's  
11 ability to comprehend pharmaceutical guidance and support over the tele-  
12 phone, determines that a drug as prescribed on an individual basis is  
13 most appropriately filled at a retail location, provided that an in-net-  
14 work retail pharmacy of the patient's choosing agrees to the same  
15 reimbursement amount and is able to fill the prescription, the  
16 prescriber's determination shall be final.

17 § 12. The insurance law is amended by adding a new section 3224-e to  
18 read as follows:

19 § 3224-e. Prescription synchronization. (a) Every individual or group  
20 health insurance policy providing prescription drug coverage when appli-  
21 cable to permit synchronization shall permit and apply a daily prorated  
22 cost-sharing rate to prescriptions that are dispensed by a network phar-  
23 macy for less than a thirty day supply, when it is agreed among the  
24 covered individual, a health care practitioner, and a pharmacist that  
25 synchronization of multiple prescriptions for the treatment of a chronic  
26 illness is in the best interest of the covered individual for the  
27 management or treatment of that chronic illness provided that all of the  
28 following apply:

29 (1) the medications are covered by the policy or plan;

30 (2) the medications are used for treatment and management of chronic  
31 conditions that are subject to refills;

32 (3) the medications are not a schedule II controlled substance or a  
33 schedule III controlled substance containing hydrocodone;

34 (4) the medications meet all prior authorization criteria specific to  
35 medications at the time of the synchronization request;

36 (5) the medications are of a formulation that can be effectively split  
37 over required short fill periods to achieve synchronization; and

38 (6) the medications do not have quantity limits or dose optimization  
39 criteria or requirements that would be violated in fulfilling synchroni-  
40 zation.

41 (b) No individual or group health insurance policy providing  
42 prescription drug coverage shall deny coverage for the dispensing of a  
43 medication for partial fill when it is for purposes of synchronizing the  
44 patient's medications. When applicable to permit synchronization, every  
45 individual or group health insurance policy must allow a pharmacy to  
46 override any denial codes indicating that a prescription is being  
47 refilled too soon for the purposes of medication synchronization.

48 (c) Dispensing fees for partially filled or refilled prescriptions  
49 shall be paid in full for each prescription dispensed, regardless of any  
50 pro-rated copay for the beneficiary or fee paid for alignment services.

51 (d) Nothing in this section shall be deemed to require health care  
52 practitioners and pharmacists to synchronize the refilling of multiple  
53 prescriptions for a covered individual.

54 (e) The requirements of this section shall apply only once for each  
55 prescription drug subject to medication synchronization except when  
56 either of the following occurs:

1 (1) the prescriber changes the dosage or frequency of administration  
2 of the prescription drug subject to a medication synchronization; or  
3 (2) the prescriber prescribes a different drug.

4 § 13. The insurance law is amended by adding a new section 4303-b to  
5 read as follows:

6 § 4303-b. Prescription synchronization. (a) Every hospital service  
7 corporation and health service corporation providing prescription drug  
8 coverage when applicable to permit synchronization shall permit and  
9 apply a daily prorated cost-sharing rate to prescriptions that are  
10 dispensed by a network pharmacy for less than a thirty day supply, when  
11 it is agreed among the covered individual, a health care practitioner,  
12 and a pharmacist that synchronization of multiple prescriptions for the  
13 treatment of a chronic illness is in the best interest of the covered  
14 individual for the management or treatment of that chronic illness  
15 provided that all of the following apply:

16 (1) the medications are covered by the policy or plan;

17 (2) the medications are used for treatment and management of chronic  
18 conditions that are subject to refills;

19 (3) the medications are not a schedule II controlled substance or a  
20 schedule III controlled substance containing hydrocodone;

21 (4) the medications meet all prior authorization criteria specific to  
22 medications at the time of the synchronization request;

23 (5) the medications are of a formulation that can be effectively split  
24 over required short fill periods to achieve synchronization; and

25 (6) the medications do not have quantity limits or dose optimization  
26 criteria or requirements that would be violated in fulfilling synchroni-  
27 zation.

28 (b) No hospital service corporation or health service corporation  
29 providing prescription drug coverage shall deny coverage for the  
30 dispensing of a medication for partial fill when it is for purposes of  
31 synchronizing the patient's medications. When applicable to permit  
32 synchronization, every hospital service corporation or health service  
33 corporation providing prescription drug coverage must allow a pharmacy  
34 to override any denial codes indicating that a prescription is being  
35 refilled too soon for the purposes of medication synchronization.

36 (c) Dispensing fees for partially filled or refilled prescriptions  
37 shall be paid in full for each prescription dispensed, regardless of any  
38 pro-rated copay for the beneficiary or fee paid for alignment services.

39 (d) Nothing in this section shall be deemed to require health care  
40 practitioners and pharmacists to synchronize the refilling of multiple  
41 prescriptions for a covered individual.

42 (e) The requirements of this section shall apply only once for each  
43 prescription drug subject to medication synchronization except when  
44 either of the following occurs:

45 (1) The prescriber changes the dosage or frequency of administration  
46 of the prescription drug subject to a medication synchronization; or

47 (2) The prescriber prescribes a different drug.

48 § 14. Subdivision 9 of section 367-a of the social services law is  
49 amended by adding a new paragraph (j) to read as follows:

50 (j) (i) The department of health shall establish a program for  
51 synchronization of medications when it is agreed among the recipient, a  
52 provider and a pharmacist that synchronization of multiple prescriptions  
53 for the treatment of a chronic illness is in the best interest of the  
54 patient for the management or treatment of a chronic illness provided  
55 that the medications:

56 (A) are covered by the department of health pursuant to this title;

1 (B) are used for treatment and management of chronic conditions that  
2 are subject to refills;

3 (C) are not a schedule II controlled substance or a schedule III  
4 controlled substance containing hydrocodone;

5 (D) meet all prior authorization criteria specific to the medications  
6 at the time of the synchronization request;

7 (E) are of a formulation that can be effectively split over required  
8 short fill periods to achieve synchronization; and

9 (F) do not have quantity limits or dose optimization criteria or  
10 requirements that would be violated in fulfilling synchronization.

11 (ii) The department of health shall not deny coverage for the dispens-  
12 ing of a medication by a network pharmacy for a partial supply when it  
13 is for the purpose of synchronizing the patient's medications. When  
14 applicable to permit synchronization, the department of health shall  
15 allow a pharmacy to override any denial codes indicating that a  
16 prescription is being refilled too soon for the purposes of medication  
17 synchronization.

18 (iii) To permit synchronization, the department of health shall apply  
19 a prorated daily cost-sharing rate to any medication dispensed by a  
20 network pharmacy pursuant to this section.

21 (iv) The dispensing fee paid to a network pharmacy contracted to  
22 provide services pursuant to this section for a partial supply associ-  
23 ated with a medication synchronization shall be paid in full and shall  
24 not be prorated.

25 (v) The requirements of this paragraph applies only once for each  
26 prescription drug subject to medication synchronization except when  
27 either of the following occurs:

28 (A) the prescriber changes the dosage or frequency of administration  
29 of the prescription drug subject to a medication synchronization; or

30 (B) the prescriber prescribes a different drug.

31 (vi) Nothing in this paragraph shall be deemed to require health care  
32 practitioners and pharmacists to synchronize the refilling of multiple  
33 prescriptions for a recipient.

34 § 15. Subdivision 4 of section 364-j of the social services law is  
35 amended by adding a new paragraph (x) to read as follows:

36 (x) (i) The department of health or a managed care organization  
37 contracted to provide services pursuant to this section shall establish  
38 a program for synchronization of medications when it is agreed among the  
39 recipient, a provider and a pharmacist that synchronization of multiple  
40 prescriptions for the treatment of a chronic illness is in the best  
41 interest of the patient for the management or treatment of a chronic  
42 illness provided that the medications:

43 (A) are covered by Medicaid services or a managed care organization  
44 contracted to provide services pursuant to this chapter;

45 (B) are used for treatment and management of chronic conditions that  
46 are subject to refills;

47 (C) are not a schedule II controlled substance or a schedule III  
48 controlled substance containing hydrocodone;

49 (D) meet all prior authorization criteria specific to the medications  
50 at the time of the synchronization request;

51 (E) are of a formulation that can be effectively split over required  
52 short fill periods to achieve synchronization; and

53 (F) do not have quantity limits or dose optimization criteria or  
54 requirements that would be violated in fulfilling synchronization.

55 (ii) The department of health or a managed care organization  
56 contracted to provide services under this section shall not deny cover-

1 age for the dispensing of a medication by a network pharmacy for a  
2 partial supply when it is for the purpose of synchronizing the patient's  
3 medications. When applicable to permit synchronization, the department  
4 of health or a managed care organization contracted to provide services  
5 under this title shall allow a pharmacy to override any denial code  
6 indicating that a prescription is being refilled too soon for the  
7 purposes of medication synchronization.

8 (iii) To permit synchronization, the department of health or a managed  
9 care organization contracted to provide services pursuant to this title  
10 shall apply a prorated daily cost-sharing rate to any medication  
11 dispensed by a network pharmacy pursuant to this section.

12 (iv) The dispensing fee paid to a network pharmacy contracted to  
13 provide services pursuant to this section for a partial supply associ-  
14 ated with a medication synchronization shall be paid in full and shall  
15 not be prorated.

16 (v) The requirements of this paragraph applies only once for each  
17 prescription drug subject to medication synchronization except when  
18 either of the following occurs:

19 (A) the prescriber changes the dosage or frequency of administration  
20 of the prescription drug subject to a medication synchronization; or

21 (B) the prescriber prescribes a different drug.

22 (vi) Nothing in this paragraph shall be deemed to require health care  
23 practitioners and pharmacists to synchronize the refilling of multiple  
24 prescriptions for a covered individual.

25 § 16. Subsection (h) of section 4325 of the insurance law, as added by  
26 chapter 487 of the laws of 2010, is amended to read as follows:

27 (h) (i) No corporation or insurer organized or licensed under this  
28 chapter which provides coverage for prescription drugs shall require, or  
29 enter into a contract which permits, a copayment which exceeds the usual  
30 and customary cost of such prescribed drug or which exceeds the total  
31 price paid to the pharmacy for such prescribed drug after the insured  
32 has met the annual deductible requirement.

33 (ii) In determining any coinsurance amount required to be paid for a  
34 prescription drug, no insurer or corporation organized under this chap-  
35 ter shall base its computation on a price higher than the actual price  
36 paid by the pharmacy for the drug, taking into account any rebates  
37 specific to the drug. The department of financial services shall issue  
38 regulations setting forth the method each insurer or corporation organ-  
39 ized under this chapter must use to determine the actual price paid by  
40 the pharmacy.

41 (iii) Each insurer or corporation licensed under this article which  
42 offers prescription drug coverage must itself or through its pharmacy  
43 benefit manager issue a written explanation of benefit form to its  
44 enrollees with respect to each prescription filled, containing all cate-  
45 gories of information required of explanation of benefits forms for  
46 medical benefits.

47 § 17. Subdivision 6 of section 6810 of the education law is amended by  
48 adding a new paragraph (b-1) to read as follows:

49 (b-1) The prescriber or pharmacist shall inform the patient whether  
50 the prescriber or pharmacist has prescribed or substituted a different  
51 generic drug product from the generic drug product the patient has  
52 previously received. Notification required pursuant to this paragraph  
53 shall be provided both written and orally, contemporaneously with the  
54 filling of the prescription.

55 § 18. Section 6826-a of the education law is amended by adding a new  
56 subdivision 3 to read as follows:

1 3. The copayment amount shall not exceed the total price paid to the  
2 pharmacy for the prescribed drug, except in cases where the insured has  
3 not met the annual deductible requirement. The copayment charged to a  
4 consumer for a prescription drug shall not exceed the amount which would  
5 be charged if the drug were purchased without insurance coverage.

6 § 19. Paragraph 1 of subsection (e) of section 3231 of the insurance  
7 law is amended by adding a new subparagraph (C) to read as follows:

8 (C) an insurer shall annually certify to the department that, during  
9 the prior benefit year, the insurer made available to enrollees at the  
10 point of sale at least a majority (i.e., greater than fifty percent) of  
11 the rebates.

12 (i) For purposes of this subparagraph, "rebate" means:

13 (1) negotiated price concessions including but not limited to base  
14 rebates and reasonable estimates of any price protection rebates and  
15 performance-based rebates that may accrue directly or indirectly to the  
16 issuer during the coverage year from a manufacturer, dispensing pharma-  
17 cy, or other party to the transaction; and

18 (2) reasonable estimates of any fees and other administrative costs  
19 that are passed through to the issuer and serve to reduce the issuer's  
20 prescription drug liabilities for the coverage year.

21 (ii) In providing the certification required under this section, an  
22 issuer shall not publish or otherwise reveal information regarding the  
23 actual amount of rebates the issuer received on a product-, manufactur-  
24 er-, or pharmacy-specific basis. Such information is protected as a  
25 trade secret, is not a public record as defined in the public officers  
26 law and shall not be disclosed directly or indirectly. An insurer shall  
27 impose the confidentiality protections of this section on any third  
28 parties or vendors with which it contracts that may receive or have  
29 access to rebate information.

30 § 20. Subsection (b) of section 3221 of the insurance law is amended  
31 to read as follows:

32 (b) (1) No such policy shall be delivered or issued for delivery in  
33 this state unless a schedule of the premium rates pertaining to such  
34 form shall have been filed with the superintendent.

35 (2) An insurer shall annually certify to the department that, during  
36 the prior benefit year, the insurer made available to enrollees at the  
37 point of sale at least a majority (i.e., greater than fifty percent) of  
38 the rebates.

39 (A) For purposes of this paragraph, "rebate" means:

40 (i) Negotiated price concessions including but not limited to base  
41 rebates and reasonable estimates of any price protection rebates and  
42 performance-based rebates that may accrue directly or indirectly to the  
43 issuer during the coverage year from a manufacturer, dispensing pharma-  
44 cy, or other party to the transaction; and

45 (ii) Reasonable estimates of any fees and other administrative costs  
46 that are passed through to the issuer and serve to reduce the issuer's  
47 prescription drug liabilities for the coverage year.

48 (B) In providing the certification required under this section, an  
49 issuer shall not publish or otherwise reveal information regarding the  
50 actual amount of rebates the issuer received on a product-, manufactur-  
51 er-, or pharmacy-specific basis. Such information is protected as a  
52 trade secret, is not a public record as defined in the public officers  
53 law and shall not be disclosed directly or indirectly. An insurer shall  
54 impose the confidentiality protections of this section on any third  
55 parties or vendors with which it contracts that may receive or have  
56 access to rebate information.

1 § 21. Severability. If any item, clause, sentence, subparagraph,  
2 subdivision or other part of this act, or the application thereof to any  
3 person or circumstances shall be held to be invalid, such holding shall  
4 not affect, impair or invalidate the remainder of this act but it shall  
5 be confined in its operation to the item, clause, sentence, subpara-  
6 graph, subdivision or other part of this act directly involved in such  
7 holding, or to the person and circumstances therein involved.

8 § 22. This act shall take effect immediately and shall apply to insur-  
9 ance policies issued, amended, or renewed on or after January 1, 2026;  
10 provided, however, that the amendments to subdivision 9 of section 367-a  
11 of the social services law made by section fourteen of this act shall  
12 not affect the expiration of such subdivision pursuant to section 4 of  
13 chapter 19 of the laws of 1998, as amended, and shall expire therewith;  
14 and provided, further, that the amendments to section 364-j of the  
15 social services law made by section fifteen of this act shall not affect  
16 the repeal of such section and shall be deemed repealed therewith.  
17 Effective immediately, the addition, amendment and/or repeal of any rule  
18 or regulation necessary for the implementation of this act on its effec-  
19 tive date are authorized to be made and completed on or before such  
20 date.